RxDoctor Payments Data

Nicolas Dejong, PA

Physician Assistant · Oxnard, CANPI 1902204803

Payments from drug & device makers

$1,299in general payments, 2019–2025

Across 60 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$402
  • AstraZeneca$318
  • GSK$131
  • Lilly USA, LLC$106
  • Optinose US, Inc.$56
  • Shield Therapeutics Inc$55
  • plus $230 from 6 others

What the payments were for

  • Food & beverage$1,299100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,299 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$70,062
Medicare patients
285
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$114,202
EliquisApixaban47$47,332
TrulicityDulaglutide37$42,136
JanuviaSitagliptin Phosphate20$29,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,884
FarxigaDapagliflozin Propanediol25$25,607
JardianceEmpagliflozin31$24,457
RybelsusSemaglutide19$24,080
LinzessLinaclotide27$22,548
MyrbetriqMirabegron19$14,442
MounjaroTirzepatide12$12,019
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$5,188
Ondansetron Hcl13$4,643
Atorvastatin Calcium406$3,421
LantusInsulin Glargine,hum.Rec.Anlog19$3,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$402$138,282134 claims
Lilly USA, LLCTrulicity, Mounjaro$106$54,15549 claims
GSKTrelegy Ellipta$131$25,88433 claims
AstraZenecaFarxiga$318$25,60725 claims
Boehringer IngelheimJardiance$48$24,45731 claims
AbbVieLinzess$27$22,54827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →